Two Sigma Advisers
VIRX

Two Sigma Advisers’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Two Sigma Advisers’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,719
Closed -$17.9K – 2616
2023
Q2 		$17.9K Sell
12,719
-3,000
-19% -$4.29K ﹤0.01% 2327
2023
Q1 		$25K Sell
15,719
-25,300
-62% -$46K ﹤0.01% 2508
2022
Q4 		$59.9K Buy
41,019
+29,919
+270% +$87.4K ﹤0.01% 2346
2022
Q3 		$47K Sell
11,100
-1,900
-15% -$8.05K ﹤0.01% 2378
2022
Q2 		$50K Sell
13,000
-4,418
-25% -$12.6K ﹤0.01% 2482
2022
Q1 		$83K Sell
17,418
-30,726
-64% -$92.6K ﹤0.01% 2531
2021
Q4 		$176K Buy
+48,144
New +$257K ﹤0.01% 2312
2020
Q3 		– Sell
-321
Closed -$3K – 2668
2020
Q2 		$3K Sell
321
-243
-43% -$3.66K ﹤0.01% 2474
2020
Q1 		$8K Sell
564
-2,028
-78% -$44K ﹤0.01% 2430
2019
Q4 		$31K Buy
2,592
+2,060
+387% +$34.5K ﹤0.01% 2308
2019
Q3 		$13K Sell
532
-169
-24% -$4.88K ﹤0.01% 2190
2019
Q2 		$18K Buy
701
+237
+51% +$9.17K ﹤0.01% 2281
2019
Q1 		$20K Sell
464
-20
-4% -$453 ﹤0.01% 2256
2018
Q4 		$7K Sell
484
-89
-16% -$3.63K ﹤0.01% 2328
2018
Q3 		$40K Buy
573
+17
+3% +$1.29K ﹤0.01% 2187
2018
Q2 		$41K Buy
+556
New +$49.5K ﹤0.01% 2311
2015
Q1 		– Sell
-170
Closed -$91K – 2460
2014
Q4 		$91K Sell
170
-170
-50% -$76.6K ﹤0.01% 2340
2014
Q3 		$509K Buy
+340
New +$492K ﹤0.01% 1531

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers's VIRX Position: Q3 2023 in Review

Two Sigma Advisers sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2023, closing a stake of 12,719 shares — an estimated $17.9K sold.

Two Sigma Advisers first reported a position in VIRX in Q3 2014 and held it in 18 quarters. The position peaked at $509K in Q3 2014. 42 funds tracked by Wall St. Rank hold VIRX as of Q3 2023.

  • Two Sigma Advisers reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 12,719 Viracta Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $17.9K.
  • Two Sigma Advisers first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2014 and held it in 18 quarters.
  • Two Sigma Advisers's Viracta Therapeutics, Inc. Common Stock position peaked at $509K in Q3 2014.
  • 42 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Two Sigma Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.